To all,
Vivus (NASDAQ:VVUS) rises after positive analyst comments
Reuters, Wednesday, September 03, 1997 at 16:02
LOS ANGELES, Sept 3 (Reuter) - Shares of Vivus Inc rose
sharply Wednesday after a PaineWebber analyst forecast a strong
third quarter for the maker of male impotence treatments.
PaineWebber analyst Charles Olsziewski said he expects the
company to earn $0.20 per share on a fully taxed basis in the
third quarter, up from $0.07 in the year-ago quarter.
Olsziewski also noted Vivus shares have risen 55 percent
year to date, more than twice the rise of the overall market.
Vivus shares Wednesday were up 1-9/16 to 29-13/16.
The analyst also said Vivus' Muse product is expected to be
approved in the U.K. by the end of September, which will earn
the company a $2 million milestone payment.
"We continue to believe that Muse is a safe and effective
therapy for the majority of men afflicted with erectile
dysfunction," Olsziewski said in his report.
"...Our sense is that within the next 12-24 months, Vivus will
become more than a one-product company, using its cash-rich
balance sheet and stock to acquire additional products or
technologies in the urology area."
Vivus' Muse treatment is an ultrathin applicator containing
a medication that impotent men can insert into the tip of their
penises to produce an erection within about 10 minutes.
Copyright 1997, Reuters News Service
I hope that we can push through 32 soon !
Kellis |
